Sesen Bio, Inc.

Albumedix Limited

Eleven Biotherapeutics, Inc.

Michael March Schmidt

Eric Steven Furfine

Thomas M Barnes

Alison Tisdale

David V Erbe

Grigorios Zarbis-Papastoitsis

Amy Jada Andreucci

Interleukin-6 (IL-6) antagonists are provided that are specific for binding to site II of IL-6. Methods of using such inhibitors to treat IL-6 related diseases, e.g., disease of the eye such as diabetic macular edema are disclosed.

IL-6 antagonists and uses thereof

Improved IL-6 antibodies are provided. Uses of the antibodies in the treatment of IL-6-related diseases, e.g., ocular diseases such as diabetic macular edema, are disclosed.

IL-6 antibodies

The invention provides methods and materials for making and using variant serum albumin amino acid sequences which exhibit improved properties compared to wild type serum albumin sequences. The invention further provides methods and materials for making and using fusion proteins in which the variant serum albumin amino acid sequences are fused to a therapeutic or diagnostic agent, such as a therapeutic protein, or a functional fragment or variant thereof that maintains activity, and exhibits improved properties.

Variant serum albumin with improved half-life and other properties

Interleukin 6 (IL-6) antagonists are provided that are specific for binding to site II of IL-6. Methods of using such inhibitors to treat IL-6 related diseases, e.g., disease of the eye such as diabetic macular edema are disclosed.

Growing community of inventors

Boston, MA, United States of America

Michael March Schmidt